Momentum Events is organizing the IP Counsel Exchange for Biosimilar Applicants & Sponsors on January 23-24, 2014 in New York, USA.
A Step-by-Step Guide to Successfully Navigating Uncharted Waters and Best Positioning Your IP Rights to Survive in the Emerging Biosimilars Landscape Who You Will Meet at the The Biosimilars IP Counsel Exchange: Senior legal counsel within companies and in private practice representing leading pharmaceutical, biopharmaceutical and biotechnology companies who practice in:
- IPR, Intellectual property and patents
- IP licensing
- Patent and IP litigation
- Patent portfolio management
- Legal affairs
As opposed to the Paragraph IV Hatch-Waxman mechanism which put in place the Orange Book for brand name and generic pharmaceutical companies to easily access, those who are seeking to conduct their own IP due diligence and effectively mine the current patent landscape when breaking into the biosimilars market have no such luxury. Instead potential manufacturers must engage in an extensive search of the public landscape followed by contentious, behind closed doors discussions with the parent biologic manufacturer – and all this just to determine which IP rights may ultimately become the subject of controversy.
Specifically developed to provide a forum for IP counsel within the pharmaceutical, biopharmaceutical and biotechnology space, the IP Counsel Biosimilars Exchange will focus in on providing participants with best practices and proven strategies for best positioning your biosimilar/biobetter product to obtain market exclusivity. Addressing the true points of contention for counsel who are living and breathing these issues as we speak, attendees of this unique and highly-focused two-day event will walk away with a step-by-step playbook for effectively navigating the evolving IP landscape currently surrounding biologic, biosimilar and biobetter products.
To register or learn more, visit www.momentumevents.com/biosimilars or call 646-807-8555.